Drug · CHEMBL526

PROPOFOL

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. PROPOFOL. Drugs and targets, record CHEMBL526. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL526

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: PROPOFOL; ChEMBL
ChEMBL ID: CHEMBL526; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Diprivan, Disoprivan, Propofol component of ketafol, Rapinovet; ChEMBL
Other names: Disoprofol, Fresofol, ICI 35,868, ICI 35-868, ICI-35868, ICI35,868, Lipuro, NSC-5105, Phenol, 2,6-bis(1-methylethyl); ChEMBL
DrugBank: DB00818; DrugBank
InChIKey: OLBCVFGFOZPWHH-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, as Open Targets' drug record gives it; Open Targets

Targets16

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
GABRA1	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2554
GABRA2	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2555
GABRA3	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2556
GABRA4	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2557
GABRA5	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2558
GABRA6	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2559
GABRB1	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2560
GABRB2	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2561
GABRB3	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2562
GABRD	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2563

1 to 10 of 16Source ChEMBL

See all 16 targets

Diseases152

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
sedation	Phase 3	ClinicalTrials.gov	39	39	https://conductscience.org/library/drugs?q=EFO_0009868
hypotensive disorder	Phase 3	ClinicalTrials.gov	13	13	https://conductscience.org/library/drugs?q=MONDO_0005468
delirium	Phase 3	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=MONDO_0045057
breast cancer	Phase 3	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0007254
colorectal cancer	Phase 3	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0005575
major depressive disorder	Phase 2/3	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0002009
depressive disorder	Phase 2/3	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0002050
acute respiratory distress syndrome	Phase 3	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0006502
Hypoxemia	Phase 1/2	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=HP_0012418
Loss of consciousness	Phase 1	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=HP_0007185

1 to 10 of 152Source Open Targets

See all 152 diseases

Trials1,310

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 11 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT02625181	Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis		27,034	2019-03-07	propofol	Its name	ClinicalTrials.gov
NCT02726620	Decision Support for Intraoperative Low Blood Pressure		22,435	2019-05-16	propofol	Its name	ClinicalTrials.gov
NCT00418457	Regional Anesthesia and Breast Cancer Recurrence	Phase 3	2,108	2020-06-16	propofol	Its name	ClinicalTrials.gov
NCT02937506	Patient Satisfaction With Propofol for Out Patient Colonoscopy	Phase 4	600	2017-09-27	propofol	Its name	ClinicalTrials.gov
NCT01294163	Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery	Phase 3	509	2015-12-21	propofol	Its name	ClinicalTrials.gov
NCT00789815	Bispectral Index-guided Sedation for Flexible Bronchoscopy	Phase 4	500	2010-04-20	propofol	Its name	ClinicalTrials.gov
NCT05486416	Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery	Phase 3	465	2025-08-11	propofol	Its name	ClinicalTrials.gov
NCT01739933	The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure	Phase 3	438	2021-06-07	propofol	Its name	ClinicalTrials.gov
NCT05478174	Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia	Phase 3	400	2024-10-29	propofol	Its name	ClinicalTrials.gov
NCT01191476	Compare Pharmaceutical Economics and Efficacy of Sevoflurane With Low Fresh Gas Flow Balanced Anesthesia, Propofol Target Controlled Infusion Anesthesia and Propofol Induction Sevoflurane Maintenance Anesthesia	Phase 4	336	2012-07-03	propofol	Its name	ClinicalTrials.gov

1 to 10 of 1,310

See all 1,310 trials

Comparisons in its trials273

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Hypotension Decision Support vs Usual Care Group: deaths from any cause	158 of 4,972	534 of 17,463	22,435	NCT02726620	Trial comparisons
Hypotension Decision Support vs Usual Care Group: serious adverse events	541 of 4,972	1,811 of 17,463	22,435	NCT02726620	Trial comparisons
Hypotension Decision Support vs Usual Care Group: Incidence of a MAP < 50 mmHg for > 20 Minutes	85 of 4,328	304 of 15,624	19,952	NCT02726620	Trial comparisons
Hypotension Decision Support vs Usual Care Group: Usage Frequency of Cardiovascular Drugs: Glycopyrrolate	1,257 of 4,328	11,093 of 15,624	19,952	NCT02726620	Trial comparisons
Hypotension Decision Support vs Usual Care Group: Usage Frequency of Cardiovascular Drugs: Ephinephrine	409 of 4,328	1,215 of 15,624	19,952	NCT02726620	Trial comparisons
Hypotension Decision Support vs Usual Care Group: Incidence of a MAP < 60 mmHg	3,798 of 4,328	13,779 of 15,624	19,952	NCT02726620	Trial comparisons
Hypotension Decision Support vs Usual Care Group: Incidence of a MAP < 50 mmHg for > 10 Minutes	326 of 4,328	1,159 of 15,624	19,952	NCT02726620	Trial comparisons
Hypotension Decision Support vs Usual Care Group: Usage Frequency of Cardiovascular Drugs: Phenylephrine	3,685 of 4,328	12,211 of 15,624	19,952	NCT02726620	Trial comparisons
Hypotension Decision Support vs Usual Care Group: In-hospital Mortality	137 of 4,328	487 of 15,624	19,952	NCT02726620	Trial comparisons
Hypotension Decision Support vs Usual Care Group: Incidence of a MAP < 55 mmHg	3,045 of 4,328	10,991 of 15,624	19,952	NCT02726620	Trial comparisons

1 to 10 of 273

See all 273 comparisons in its trials

Papers from its trials684

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40315032	RESULT	1	PubMed
40098564	RESULT	1	PubMed
40090678	RESULT	2	PubMed
39564442	RESULT	1	PubMed
39193191	RESULT	1	PubMed
39179443	RESULT	1	PubMed
38534990	RESULT	1	PubMed
38443286	RESULT	1	PubMed
38305707	RESULT	1	PubMed
38293492	RESULT	1	PubMed

1 to 10 of 684

See all 684 papers from its trials

Tests in its trials21

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Symbol Coding	9	7	ConductCognition
Trail Making Test A	6	4	ConductCognition
Trail Making Test B	6	4	ConductCognition
Verbal Learning	6	5	ConductCognition
Verbal Fluency	5	4	ConductCognition
Stroop Color-Word Test	4	4	ConductCognition
Digit Span Test	3	3	ConductCognition
Paced Visual Serial Addition Test	2	1	ConductCognition
Remember and Know Test	2	2	ConductCognition
Cancellation Test	1	1	ConductCognition

1 to 10 of 21

See all 21 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL526

GET https://conductscience.org/api/drugs/v1/CHEMBL526/diseases?page=2

API reference For AI assistants